My bookmarksSign up free
Source

Commission Delegated Regulation (EU) 2021/756 of 24 March 2021 amending Regulation (EC) No 1234/2008 concerning the examination of variations to the terms of marketing authorisations for medicinal products for human use and veterinary medicinal products (Text with EEA relevance)

Commission Delegated Regulation (EU) 2021/756 of 24 March 2021 amending Regulation (EC) No 1234/2008 concerning the examination of variations to the terms of marketing authorisations for medicinal products for human use and veterinary medicinal products (Text with EEA relevance)

Delegated Regulation (EU) 2021/756 · Regulation · 2 articles

Data as of 2026-07-04 · Compiled from an official source version. Later amendments or repeals may not be reflected; the official text prevails. · Read the official text ↗

Pandemic situation with respect to human influenza and human coronavirus

Article 1

Open ↗

Regulation (EC) No 1234/2008 is amended as follows: (1) Article 21 is replaced by the following ‘Article 21 Pandemic situation with respect to human influenza and human coronavirus (1)   By way of derogation from Chapters I, II, IIa and III, where a pandemic situation with respect to human influenza or human coronavirus is duly recognised by the World Health Organization or by the Union in the framework of Decision No 1082/2013/EU of the European Parliament and of the Council  ( *1 ) , the relevant authorities, or in the case of centralised marketing authorisations, the Commission may, where certain pharmaceutical, non-clinical or clinical data are missing, exceptionally and temporarily accept a variation to the terms of a marketing authorisation for a human influenza vaccine or a human coronavirus vaccine. (2)   The relevant authority may request the applicant to provide supplementary information in order to complete its assessment within a time limit set by it. (3)   Variations may be accepted pursuant to paragraph 1 only if the benefit-risk balance of the medicinal product is favourable. (4)   Where a variation is accepted pursuant to paragraph 1, the holder shall submit the missing pharmaceutical, non-clinical and clinical data within a time limit set by the relevant authority. (5)   In the case of centralised marketing authorisations, the missing data and the time limit for submission or compliance shall be specified in the conditions to the marketing authorisation. Where the marketing authorisation has been granted in accordance with Article 14-a of Regulation (EC) No 726/2004 this may be done as part of the specific obligations referred to in paragraph 4 of that Article. ( *1 )   Decision No 1082/2013/EU of the European Parliament and of the Council of 22 October 2013 on serious cross-border threats to health and repealing Decision No 2119/98/EC ( OJ L 293, 5.11.2013, p. 1 ).’ " (2) In point (a) of Article 23(1 a ) the following point (ix) is added: ‘(ix) variations related to changes to the active substance of a human coronavirus vaccine, including replacement or addition of a serotype, strain, antigen or coding sequence or combination of serotypes, strains, antigens or coding sequences;’ (3) In point 1 of Annex I, point (c) is replaced by the following: ‘(c) replacement of a biological active substance with one of a slightly different molecular structure where the efficacy and/or safety characteristics are not significantly different, with the exception of: — changes to the active substance of a seasonal, pre-pandemic or pandemic vaccine against human influenza; — replacement or addition of a serotype, strain, antigen or coding sequence or combination of serotypes, strains, antigens or coding sequences for a human coronavirus vaccine; — replacement or addition of a serotype, strain, antigen or combination of serotypes, strains or antigens for a veterinary vaccine against avian influenza, foot-and-mouth disease or bluetongue; — replacement of a strain for a veterinary vaccine against equine influenza;’ (4) In point 2 of Annex II the following point (l) is added: ‘(l) variations related to the replacement or addition of a serotype, strain, antigen or coding sequence or combination of serotypes, strains, antigens or coding sequences for a human coronavirus vaccine.’

Article 2

Open ↗

This Regulation shall enter into force on the third day following that of its publication in the Official Journal of the European Union .

Other acts of the same type
Commission Delegated Regulation (EU) 2025/927 of 20 May 2025 supplementing Directive 2003/87/EC of the European Parliament and of the Council as regards measures adopted by the International Civil Aviation Organization for the monitoring, reporting and verification of aviation emissions for the purpose of implementing a global market-based measure and repealing Commission Delegated Regulation (EU) 2019/1603Council Regulation (EU) 2025/932 of 20 May 2025 amending Regulation (EU) No 833/2014 concerning restrictive measures in view of Russia’s actions destabilising the situation in UkraineCouncil Implementing Regulation (EU) 2025/933 of 20 May 2025 implementing Regulation (EU) No 269/2014 concerning restrictive measures in respect of actions undermining or threatening the territorial integrity, sovereignty and independence of UkraineCouncil Implementing Regulation (EU) 2025/958 of 20 May 2025 implementing Regulation (EU) 2024/1485 concerning restrictive measures in view of the situation in RussiaCouncil Implementing Regulation (EU) 2025/959 of 20 May 2025 implementing Regulation (EU) 2018/1542 concerning restrictive measures against the proliferation and use of chemical weaponsCouncil Regulation (EU) 2025/964 of 20 May 2025 amending Regulation (EU) 2024/2642 concerning restrictive measures in view of Russia’s destabilizing activitiesCouncil Implementing Regulation (EU) 2025/965 of 20 May 2025 implementing Regulation (EU) 2024/2642 concerning restrictive measures in view of Russia’s destabilising activitiesCouncil Implementing Regulation (EU) 2025/968 of 20 May 2025 implementing Regulation (EU) 2024/2642 concerning restrictive measures in view of Russia’s destabilizing activitiesCommission Delegated Regulation (EU) 2025/1045 of 20 May 2025 amending Regulation (EU) 2019/1242 of the European Parliament and of the Council as regards the addition of vehicle sub-groups for extra-heavy-combination lorriesCommission Implementing Regulation (EU) 2025/899 of 19 May 2025 amending Annex IV to Implementing Regulation (EU) 2021/404 as regards the entry for Thailand in the list of third countries or territories or zones thereof authorised for the entry into the Union of consignments of equine animalsCommission Implementing Regulation (EU) 2025/901 of 19 May 2025 establishing a list of substances which are essential for the treatment of equine species, or which bring added clinical benefit compared to other treatment options available for equine species and for which the withdrawal period for equine species shall be six months and repealing Regulation (EC) No 1950/2006Commission Implementing Regulation (EU) 2025/912 of 19 May 2025 laying down rules for the application of Regulation (EU) 2024/1991 of the European Parliament and of the Council as regards a uniform format for the national restoration plan

Source: EUR-Lex (Publications Office of the EU), © European Union, reuse permitted under Commission Decision 2011/833/EU.

Contents

What to look at next